INTRAVITREAL TRIAMCINOLONE ALONE VERSUS COMBINED INTRAVITREAL TRIAMCINOLONE AND BEVACIZUMAB ON CENTRAL MACULAR THICKNESS IN DIABETIC MACULAR EDEMA
Triamcinolone Versus Bevacizumab on Central Macular Thickness
Objective: To compare the effect of intravitreal triamcinolone (IVT) alone with combined intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IVB) on central macular thickness (CMT) in patients of diabetic macular edema (DME).
Study Design: Randomized control trial.
Place and Duration of Study: Armed Forces Institute of Ophthalmology, Jun 2013 to Dec 2013.
Material and Methods: Eighty patients were included in the study through non probability consecutive sampling and were randomized to IVT alone or IVT + IVB group using random number table. Pre and post injection (12 weeks) CMT were recorded and intra and inter group comparison was performed.
Results: Both groups showed statistically significant reduction in mean CMT at 12 weeks (p<0.05). In Group A, mean CMT reduction at 12 weeks was 64.33 microns (SD=15.17) while in Group B it was 75.18 (SD=20.82). On comparison, IVT + IVB group was more effective in reducing CMT with statistically significant difference (p=0.009).
Conclusion: Intravitreal triamcinolone used in combination with IVB is more effective in reducing central macular thickness in diabetic macular edema (DME) than intravitreal triamcinolone alone.